- Conditions
- Asthma
- Interventions
- Placebo, FP 100mcg, FP 250mcg, FP 500mcg, FSC 100/50mcg, FSC 250/50mcg, FSC500/50mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 43 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- Placebo, FP 100mcg, FP 500mcg, FP 250mcg, FSC 100/50mcg, FSC 250/50mcg, FSC 500/50mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
- Conditions
- Asthma
- Interventions
- ADVAIR 100/50mcg, ADVAIR 250/50mcg, ADVAIR 500/50mcg, FLOVENT 100mcg, FLOVENT 250mcg, FLOVENT 500mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 11,751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 350
- States / cities
- Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 273 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 13
- States / cities
- Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 17
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 13 more
- Conditions
- COPD
- Interventions
- fluticasone 100mcg/ salmeterol 50mcg, fluticasone 250/salmeterol 50, Salmeterol, salmeterol and fluticasone propionate
- Drug
- Lead sponsor
- Arthur F Gelb MD
- Individual
- Eligibility
- 20 Years to 85 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Lakewood, California
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Double-dummy placebo, Salbutamol as needed
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 13
- States / cities
- Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Xenon129 MRI imaging, Gadolinium MRI, Advair (250mcg/50mcg) one puff twice a day
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 519 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more
- Conditions
- Asthma
- Interventions
- ADVAIR 100/50mcg, ADVAIR 250/50mcg, FLOVENT 100mcg, FLOVENT 250mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 6,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 267
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 208 more
- Conditions
- Asthma
- Interventions
- fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin